Barinthus Biotherapeutics (BRNS) Operating Leases (2020 - 2026)
Barinthus Biotherapeutics' (BRNS) quarterly Operating Leases came in at $11.0 million in Q1 2026, up 10.53% YoY from $10.0 million in Q1 2025, and up 18.9% on a QoQ basis from $9.3 million in Q4 2025.
Barinthus Biotherapeutics (BRNS) Operating Leases (2020 - 2026) Analysis & Trends
Barinthus Biotherapeutics (BRNS) has 7 years of Operating Leases data on file, last reported at $11.0 million in Q1 2026.
- Quarterly Operating Leases rose 10.53% year-over-year to $11.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.0 million (up 10.53% YoY) and the FY2025 annual result came in at $9.3 million, down 8.22% from the prior year.
- Operating Leases grew to $11.0 million in Q1 2026, from $9.3 million in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $12.8 million in Q1 2024 to a low of $6.7 million in Q1 2022.
- A 5-year average of $10.3 million and a median of $10.7 million in 2023 frame the typical range for Operating Leases.
- Annual changes were most pronounced in 2022 — Operating Leases soared 500.72% — and 2025, when it decreased 22.23%.
- Tracing BRNS's Operating Leases over 5 years: stood at $8.3 million in 2022, then surged by 34.18% to $11.2 million in 2023, then declined by 9.87% to $10.1 million in 2024, then fell by 8.22% to $9.3 million in 2025, then climbed by 18.9% to $11.0 million in 2026.
- The last three Operating Leases figures came in at $11.0 million (Q1 2026), $9.3 million (Q4 2025), and $11.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Barinthus Biotherapeutics | 25.01 Mn | 25.01 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.30 Mn |
| Mar 31, 2026 | 11.01 Mn |
| Dec 31, 2025 | 9.26 Mn |
| Sep 30, 2025 | 11.57 Mn |
| Jun 30, 2025 | 11.99 Mn |
| Mar 31, 2025 | 9.96 Mn |
| Dec 31, 2024 | 10.09 Mn |
| Sep 30, 2024 | 10.68 Mn |
| Jun 30, 2024 | 10.65 Mn |
| Mar 31, 2024 | 12.81 Mn |
| Dec 31, 2023 | 11.19 Mn |
| Sep 30, 2023 | 11.20 Mn |
| Jun 30, 2023 | 12.18 Mn |
| Mar 31, 2023 | 10.65 Mn |
| Dec 31, 2022 | 8.34 Mn |
| Sep 30, 2022 | 8.07 Mn |
| Jun 30, 2022 | 8.31 Mn |
| Mar 31, 2022 | 6.74 Mn |
| Dec 31, 2021 | 6.54 Mn |
| Sep 30, 2021 | 7.73 Mn |